Skip Navigation LinksHome | Editors' Blog | Post

CMS releases Moderna booster codes following FDA approval

As the COVID public health emergency endures, you’ll find a new code that you can report when providing a Moderna booster shot, along with a complementary administration code.
 
On April 14, CMS announced a series of updates to its COVID-19 public health information, including changes to its current list of billing codes, payment allowances and effective dates. On the refreshed vaccine list, you will find two new codes for the vaccine product and administration of a Moderna booster:
  • 91309 (Severe acute respiratory syndrome coronavirus 2 [SARSCoV-2] [coronavirus disease [COVID-19]] vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use).
  • 0094A (Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 [SARSCoV-2] [coronavirus disease [COVID-19]] vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster).
The codes are effective as of March 29, 2022. The Moderna booster, which still falls under an emergency use authorization (EUA) clearance, is intended for adults 50 years and older and immunocompromised patients over the age of 18.
 
On April 16, HHS extended the COVID-19 PHE by an additional 90 days, which means it will last at least until mid-July.
 
Dosage for the new Moderna booster codes is slightly different from that of the Moderna booster codes issued Oct. 20, 2021 (91306 for the vaccine, 0064A for its administration). The October booster shot codes have a dosage of 50mcg/0.25mL. 
 
The Food and Drug Administration (FDA), which cleared the EUA of the initial Moderna vaccine in December 2020, approved a slight manufacturing change for Moderna booster doses. The booster vials will be marked with dark blue caps in contrast to the red caps were part of the non-booster doses. “This booster dose-only presentation of the Moderna COVID-19 vaccine is not authorized to provide a primary series dose,” the FDA stated in a letter approving the booster shots.
 
For additional updates from CMS, visit the COVID-19 provider toolkit online: www.cms.gov/covidvax-provider.
 
Resource
Blog Tags: CMS, COVID-19
To comment, login here.
Reader Comments (0)

Login

User Name:
Password:
Welcome to the new Part B News Online. If you are a returning user having trouble logging in, please click here.
Back to top